Gene panel testing to detect actionable genomic alterations for therapeutic purpose could test a number of cancer associated genes in a single round by advance in NGS technology, which might replace existing clinical management, including molecular testing of single gene (e. g., BRAF, ALK) or composite genetic signature (e. g., mismatch repair), in the view of cost effectiveness and time-consuming [21]. This evidence concerns the gene BRAF and cancer.